LOGIN
Etidronate, alendronate, and reisendronate significantly reduce the risk of hip fracture
March 2014
Etidronate, alendronate, and reisendronate significantly reduce the risk of hip fracture
Study Type:Meta analysis
OE Level Evidence:2
Journal Level of Evidence:N/A
Efficacy of oral bisphosphonates for preventing hip fracture in disabled patients with neurological diseases: a meta-analysis of randomized controlled trials among the Japanese population
Curr Med Res Opin. 2011 Jun;27(6):1141-8. doi: 10.1185/03007995.2011.570747. Epub 2011 Apr 1Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
Seven randomized controlled trials were included in this meta-analysis which investigated the use of oral bisphosphonates (etidronate, alendronate, or risendronate) in the prevention of hip fracture in the population suffering from neurological diseases, such as amylotrophic lateral sclerosis, stroke, or Parkinson's disease. Included studies were placebo controlled with the exception of one, which...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.